News that daclizumab, brand name Zinbryta, has been given the go-ahead to be available through the U.K.’s National Health Service (NHS) for treating relapsing MS, at least in part of the country, is good news. But why has the decision taken so long? Possibly, because the first decision, last September, was ‘no.’ The latest decision by … Continue reading After Long Wait, Zinbryta Gains Approval in Areas of the UK
There is little doubt that HSCT is controversial as a treatment, and some even say a cure, for multiple sclerosis. Some talk of great benefits; others feel the risks involved are too high. Then again, if you look at the side effects listed for the various disease modifying therapies (DMTs), they can be frightening, with death … Continue reading HSCT Is a Controversial MS Therapy. Would You Have It? I’ve Decided!